APLIF News and Press, Appili Therapeutics Inc From 06/17/21

Appili Also Provides Additional Trial Updates Appili Therapeutics Inc. (TSX: APLI) (OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases, has added several clinical research sit...

Appili Therapeutics (APLIF) announces that an independent Data and Safety Monitoring Board ((DSMB)) has recommended continuation without modification of the company's ongoing Phase 3 PRESECO COVID-19 trial.The study is evaluating the safety and efficacy of Avigan/Reeqonus, an oral antiviral t...

Independent Data Safety Monitoring Board Recommends Appili Therapeutics Complete Its Phase 3 Avigan®/Reeqonus™ Trial for Mild-to-Moderate COVID-19 Patients Appili aims to complete study and data analysis in Q3 2021 PR Newswire HALIFAX, NS , May 17, ...

Appili Therapeutics Inc. (TSX:APLI; OTCQX:APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced that the Company’s Chief Executive Officer, Dr. Armand Balboni will present at the fully virtual Bloom Burton & C...

Biotech Equity Analyst Dr. Josh Schimmer and Appili CEO Dr. Armand Balboni complete the panel, which will analyze how COVID-19 shaped pandemic preparedness, and how the world can apply lessons learned in the post-COVID era. Event time updated to 1pm ET on Wednesday, March 3 ...

Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced that it will present at the fully virtual Biocom Global conference. The Company will be discussing the role of favipirav...

Additional thought-leader panelists to be announced; advanced registration required for free online event Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced its fi...

Appili Therapeutics (APLIF): 9M GAAP EPS of -$0.16.As of Dec. 31, 2020, the Company had cash and short-term investments of $20.29M.Press Release For further details see: Appili Therapeutics beats on revenue

Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced its financial and operational results for the third quarter of its fiscal year 2021, which ended December 31, 2020. Thir...

Spartan Bioscience Board Chair Brings Broad Healthcare Experience to Appili’s Leadership Appili Therapeutics Inc. (TSX: APLI, OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious ...